Introduction {#section1-2042018819836647}
============

Type 2 diabetes (T2DM) is a progressive disease that involves stepwise addition of multiple glucose- lowering agents over time, with insulin being the most potent among them, to achieve adequate individual glycaemic targets.^[@bibr1-2042018819836647],[@bibr2-2042018819836647]^ The benefits of intensive glycaemic management in the prevention of diabetes-related complications are well established.^[@bibr3-2042018819836647][@bibr4-2042018819836647]--[@bibr5-2042018819836647]^ The current T2DM-management position statement from the Australian Diabetes Society recommends early commencement of insulin if glycaemic targets are not achieved, especially if the glycated haemoglobin (HbA1c) is above 9% (75 mmol/mol).^[@bibr1-2042018819836647]^ Insulin initiation and/or titration is a resource-intensive process requiring patient education and skill development.^[@bibr6-2042018819836647]^ This process requires a diabetes health professional, often a credentialed diabetes educator (CDE), to commence a programme for insulin dose adjustment (IDA). It requires synchronous contact between the patient and health professional, relay of blood glucose levels (BGLs), interpretation of variables influencing glucose levels and calculating new insulin doses for the patient to implement. The IDA service benefits both the patient, in achieving better clinical outcomes by appropriate insulin initiation/intensification, and the referring doctor, in improving efficiency by upgrading the role of nurse educators to adjust insulin doses according to local protocols.^[@bibr7-2042018819836647],[@bibr8-2042018819836647]^

The current IDA process has some limitations: (a) inefficiencies of time management when trying to ensure synchronous communication by phone between the health professional and patient; (b) lack of readily available patient BGLs data; (c) the possibility of transcription errors using conventional approaches of data recording *via* the telephone. These factors can lead to a suboptimal patient and health professional experience and hinder patient self-management.

With the incidence and prevalence of diabetes increasing^[@bibr9-2042018819836647]^ in a background of regional workforce shortages, continuing the current model of IDA services^[@bibr10-2042018819836647]^ is unsustainable. Insulin initiation is also often delayed,^[@bibr11-2042018819836647],[@bibr12-2042018819836647]^ particularly in primary care, and clinician-related therapeutic inertia can be an important factor that contributes to this delay^[@bibr13-2042018819836647],[@bibr14-2042018819836647]^ A process that can simplify initiation and titration of insulin may assist this clinician-related therapeutic inertia.^[@bibr13-2042018819836647],[@bibr15-2042018819836647]^

There is emerging evidence that mobile health (mHealth), a subset of Ehealth, can assist in the management of chronic disease such as diabetes.^[@bibr16-2042018819836647][@bibr17-2042018819836647]--[@bibr18-2042018819836647]^ mHealth can provide a platform for better integrated care with data availability in a systematic and organized manner,^[@bibr19-2042018819836647]^ it can be cost-saving compared with traditional care,^[@bibr20-2042018819836647],[@bibr21-2042018819836647]^ it can provide automated customized instant feedback,^[@bibr20-2042018819836647]^ and improve patient satisfaction.^[@bibr22-2042018819836647]^ These benefits of mHealth could assist in overcoming some of the limitations of the current model of IDA by enhancing self-management, organized care and easier patient access and feedback to healthcare professionals. Considering these benefits, we have designed an innovative mHealth model of IDA, that is, REthinking Model of Outpatient Diabetes care utilising EheaLth -- Insulin Dose Adjustment (REMODEL-IDA), utilizing the Mobile Diabetes Management System (MDMS). The MDMS system is described further in the 'Methods' section but in summary comprises an app for smartphones, and a web-based clinical portal. The mobile app enables patients to use a Bluetooth-enabled glucose meter to upload their BGL readings automatically to the clinical portal. The mobile app also provides an insulin diary that allows patients to manually enter the dose and time of their insulin injections. These data are subsequently transmitted and uploaded to the clinical portal *via* the internet. The primary aim of this study is to examine the effects of REMODEL-IDA on glycaemic control at 3 months in patients with T2DM. The secondary aims are to examine IDA service delivery efficiency and patient satisfaction. We hypothesize that the REMODEL-IDA model will improve glycaemic control through improved patient self-management and feedback.

Methods {#section2-2042018819836647}
=======

Setting {#section3-2042018819836647}
-------

The sites for recruitment will be the Princess Alexandra Hospital (PAH) diabetes specialist outreach community clinics and PAH diabetes telehealth clinic. These clinics accept referrals from general practitioners (GPs) for management of patients with diabetes where the ongoing management is beyond the capacity of the patient's usual GP. The diabetes specialist outreach community clinics are a model of integrated primary--secondary care where patients are seen in a community-based general practice by an advanced-skill GP and a CDE, both supervised by a visiting endocrinologist from the PAH. An advanced-skill GP is an experienced doctor who has undertaken further training in diabetes management.^[@bibr23-2042018819836647],[@bibr24-2042018819836647]^ The diabetes telehealth clinic is led by an endocrinologist and is usually supported by a GP or CDE at the recipient end.^[@bibr25-2042018819836647][@bibr26-2042018819836647]--[@bibr27-2042018819836647]^ The diabetes telehealth clinic offers teleconsultations to most hospital and health services across regional and remote Western Queensland. Both clinics review patients at regular (4 weeks to 6 months) scheduled outpatient consultations: the interval between these consultations is determined by the doctor based on the patient's glycaemic management and comorbidities. Where clinically appropriate, a proportion of patients are referred to the IDA service either for insulin initiation and/or insulin titration to achieve optimal glycaemic targets. Both clinics serve a disadvantaged population. The specialist community outreach clinics serve a population with a high proportion of low socio-economic status and the telehealth clinic serves a population with otherwise limited access to specialist services.

Current model of IDA service {#section4-2042018819836647}
----------------------------

The indications and limitations of IDA have been described earlier. Patients not meeting glycaemic targets who need to initiate insulin or adjust current insulin regimes are referred by the treating endocrinologist to the IDA service. The IDA service is performed by a CDE under the supervision of an endocrinologist. The CDE provides initial face-to-face education with the patient. Then over 4--6 weeks *via* once or twice weekly phone calls, the CDE obtains a combination of fasting, pre-meal and postprandial BGL data and provides advice to the patient on adjustment of insulin doses, if required, and general diabetes management. Most patients achieve individual target glucose levels usually within 4--6 weeks and are discharged from the service after assessment by the CDE. For the remaining individuals, a decision is made to either continue with IDA or advance their clinic appointment to identify other variables that may be influencing their glycaemic management.

Description of MDMS {#section5-2042018819836647}
-------------------

In partnership with the Australian E-Health Research Centre, the Commonwealth Scientific and Industrial Research Organisation (CSIRO) and the Department of Diabetes and Endocrinology at PAH, the Centre for Online Health, a sub-centre of the Centre for Health Services research, The University of Queensland, developed MDMS to support the transformation of the provision of specialist diabetes care. This system is modelled on a highly successful CSIRO platform that supports in-home cardiac rehabilitation leading to improvements in adherence and clinical outcomes.^[@bibr28-2042018819836647]^ The system has been modified to enable real-time monitoring of BGLs in patients with diabetes, and to support patient care. The system comprises an app for iOS- (Apple) and android-based smartphones, and a web-based clinical portal. The mobile app enables patients to use a Bluetooth-enabled glucose meter (Accu-Chek® Guide, Roche Diagnostics GmbH, Basel, Switzerland) to upload their BGL readings automatically to the clinical portal. The mobile app screen enables a review of BGL and their trends. The mobile app also provides an insulin diary that allows patients to manually enter the dose and time of their insulin injections, along with a free text comment for each dose (e.g. 'before dinner'). These data are subsequently transmitted and uploaded to the clinical portal *via* the internet. The clinical portal presents the uploaded data in graphical and tabular formats for the CDEs and endocrinologists to monitor and manage a patient's condition. Integrated alerts, which can be customized by clinicians, highlight out-of-range measures. Through the portal, the clinicians can review patients' BGL data and insulin dosages and send messages to patients' mobile phones. A summary of their diabetes care is also displayed based on the clinical information entered. Patients receive optional automated individual text-messages based on the frequency of BGL testing and BGL values. The text-messages are triggered when patients have severely low or high BGL values (\<2.5 and ⩾ 25mmol/L). All patients also receive automated text-messages based on BGL values and the frequency of BGL self-monitoring twice a week. Positive feedback messages are sent if these parameters are within clinically recommended targets. If parameters are outside of targets, the messages serve as prompts to check BGLs as recommended, to consider reasons for out-of-range BGL measurements and to seek medical advice if required. The messages also contain links to the national Diabetes Australia website for additional information regarding self-management of diabetes.

We obtained patient and clinician feedback on the MDMS through a proof-of-concept trial with patients with diabetes who had stable glycaemic management.^[@bibr29-2042018819836647]^ This facilitated enhancements to the MDMS. The MDMS will be utilized in the intervention REMODEL-IDA (see the section on the intervention group below).

Study design {#section6-2042018819836647}
------------

A two-group pilot randomized controlled trial (RCT) will be conducted for 3 months as shown in [Figure 1](#fig1-2042018819836647){ref-type="fig"}. Patients referred by the endocrinologist to the IDA service will be randomized to the intervention (REMODEL-IDA) utilizing the MDMS or control (routine care). The setting will be the sites as described above. The IDAs for the PAH diabetes specialist outreach clinics will be performed by the CDE at each site. For the PAH diabetes telehealth service, the insulin dose adjustment will be managed by the CDE at PAH except for patients of the South West Queensland Health Service where the adjustment will be conducted by the local CDE.

![Study design.\
HbA1c, glycated haemoglobin; MDMS, mobile diabetes management system; REMODEL-IDA, REthinking MOdel of Diabetes care utilizing EheaLth -- Insulin Dose Adjustment.](10.1177_2042018819836647-fig1){#fig1-2042018819836647}

### Participants {#section7-2042018819836647}

A total of 44 patients with T2DM requiring IDA services will be recruited at the participating sites. The inclusion criteria are: (a) people with T2DM pre-existing for at least 6 months; (b) age 16 years or older; (c) HbA1c 8% (64 mmol/mol) or greater (performed in the last 4 weeks before enrolment); (d) able to use a smartphone daily; (e) able to read and write in English.

Exclusion criteria will be: (a) having no access to a reliable internet connection (reliable internet connection is defined as access to 4G, 3G or Wi-Fi connection); (b) being or intending to be pregnant; (c) having type 1 diabetes; (d) enrolled in another interventional study.

### Outcomes {#section8-2042018819836647}

The primary outcome measure will be change in HbA1c. Secondary outcome measures will be: (a) serum fructosamine (short-term marker of glycaemic management over the preceding 2 weeks); (b) number of persons continuing to engage and completing IDA; (c) total time spent in IDA; (d) clinician time spent in IDA; (e) hypoglycaemic events in the preceding 2 weeks at baseline, 4 weeks and 3 months recorded and/or self-reported by the patient; (f) percentage of patients achieving HbA1c 7.5% (58 mmol/mol) or less; (g) patient satisfaction and acceptability at 4 weeks; (h) healthcare provider satisfaction from the CDE; (i) number of diabetes-related visits to the CDE, GP and/or hospital visits.

### Sample size and power calculation {#section9-2042018819836647}

We will recruit 44 patients with 22 patients in each arm, allowing for 10% attrition. This sample size for the pilot study was chosen based on previous studies.^[@bibr30-2042018819836647],[@bibr31-2042018819836647]^

### Ethics {#section10-2042018819836647}

Human Research Ethics Committee approval was obtained through the Metro South Health Human Research Ethics Committee (Ref. HREC/18/QPAH/42) and registered with Australia New Zealand Clinical Trials Registry. Trial registry ACTRN12618000412235.

### Recruitment and randomization procedure {#section11-2042018819836647}

The principal researcher will explain the study protocol to the clinical staff at the participating sites. A project officer will liaise with staff to identify potential participants for the study from those referred to the IDA service. The project officer will then screen patients for eligibility (see eligibility criteria in section on participants) and recruit patients who meet the eligibility criteria after obtaining informed consent. Ethics-approved Patient Information and Consent Forms will be used. When the patients consent to participate, they will be randomized using the Research Electronic Data Capture (REDCap) software. They will be stratified according to their residential address as regional and nonregional. Regional is defined as all areas classified under RA2 (Inner Regional), RA3 (Outer Regional), RA4 (Remote) and RA5 (Very Remote) as per the Australian Standard Geographical Standard Remoteness Areas 2011.^[@bibr32-2042018819836647],[@bibr33-2042018819836647]^ Nonregional is defined as RA1 (Major Cities). Based on a conservative recruitment rate of two patients per week, it will take 22 weeks to complete recruitment and a further 13 weeks for data collection.

### Control group {#section12-2042018819836647}

Patients referred for IDA and randomized to the control group will receive routine care provided by the clinical staff as mentioned in the section on the current model of IDA service above. The control group will be provided with standard glucose meters if their current glucose meter is more than 2 years old and followed up as per the current model of care

### Intervention group {#section13-2042018819836647}

The intervention group (see [Figure 2](#fig2-2042018819836647){ref-type="fig"}) will use the MDMS as described earlier for IDAs. All other aspects of care including face-to-face diabetes education will be similar to the control group and is as stated in the section on the current model of IDA service above.

![New model of diabetes care for insulin dose adjustment using MDMS (mobile diabetes management system).\
BGL, blood glucose level.](10.1177_2042018819836647-fig2){#fig2-2042018819836647}

For the intervention group, the researcher will install and demonstrate the mobile app on participants' individual smartphones, and provide and demonstrate the use of the Accu-Chek® Guide, which pairs *via* Bluetooth to the mobile app and sends blood glucose recordings automatically to a web-portal daily. The participants will be followed up for the duration of their enrolment into the IDA service, which can last up to 4--6 weeks. The CDE will provide advice twice weekly to the patient on insulin titration through messages sent *via* the mobile app. The participants who complete the IDA due to meeting blood glucose concentration targets before 3 months will be discharged from the MDMS but contacted at 3 months by the project officer to obtain an HbA1c. The study will be terminated for participants who continue to be in the IDA at 3 months and an HbA1c obtained. As stated above most participants will be discharged usually around 4--6 weeks, but a minority could continue with the IDA at the discretion of the CDE.

### Data collection {#section14-2042018819836647}

Study data (see [Table 1](#table1-2042018819836647){ref-type="table"}) will be collected and managed using REDCap electronic data-capture tools hosted at the University of Queensland. REDCap is a secure, web-based application designed to support data capture for research studies, providing: (a) an intuitive interface for validated data entry; (b) audit trails for tracking data manipulation and export procedures; (c) automated export procedures for seamless data downloads to common statistical packages; (d) procedures for importing data from external sources.^[@bibr34-2042018819836647]^

###### 

Schedule of enrolment, interventions and assessments.

![](10.1177_2042018819836647-table1)

  MDMS for IDA                                                 Study period -- 3 months                                                              
  ------------------------------------------------------------ -------------------------- ---------------------------------------- ----------------- -----------
                                                               Consent                    Allocation                               Post-allocation   Close-out
  TIMEPOINT                                                                               0                                        4 weeks           3 months
  ENROLMENT:                                                                                                                                         
  Eligibility screen                                           X                                                                                     
  Informed consent                                             X                                                                                     
  Allocation                                                                              X                                                          
  INTERVENTION: MDMS                                                                      ![](10.1177_2042018819836647-img2.jpg)                     
  ASSESSMENTS:                                                                                                                                       
  **Primary outcome**                                                                                                                                
   Change in HbA1c                                             X                                                                                     X
  **Secondary outcomes**                                                                                                                             
   Serum fructosamine, patient satisfaction survey,                                       X                                        X                 
   Patient acceptability of MDMS survey                                                                                            X                 
   Self-reported hypoglycaemic events survey                                              X                                        X                 X
  Healthcare provider (CDE) satisfaction survey                                                                                                      X
  Completion rate of IDA                                                                                                                             X
  Clinician time, diabetes-related visits to CDE/GP/hospital                              ![](10.1177_2042018819836647-img2.jpg)                     

CDE, credentialed diabetes educator; GP, general practitioner; HbA1c, glycated haemoglobin; IDA, insulin dose adjustment; MDMS, mobile diabetes management system.

Analysis {#section15-2042018819836647}
--------

### Statistical analysis {#section16-2042018819836647}

All analyses will be based on 'intention to treat' and per protocol (Protocol Version 3 26/10/2018). The primary analysis will be intention to treat. A secondary analysis will be based on per protocol. Differences between groups at baseline and the relevant endpoints will be compared using either the Student's *t* test or Mann--Whitney *U*-test as appropriate. A *p* value of less than 0.05 will be considered statistically significant. A subgroup analysis of the participants based on their location, regional *versus* urban, will be conducted.

Conclusion {#section17-2042018819836647}
==========

This paper describes the protocol of a pilot RCT using MDMS for IDA in T2DM for specialist community outreach and diabetes telehealth clinics across regional Queensland, Australia. This protocol builds on the previous proof-of-concept study utilizing MDMS, which showed promising levels of adherence and usability.^[@bibr29-2042018819836647]^ This study will assess a model for IDA (REMODEL-IDA) that combines mHealth interventions such as automated, personalized text-messages, provision of visual tracking of BGL patterns and feedback regarding insulin titration *via* the mobile app (MDMS). Given the potential benefits of mHealth in assisting patient self-management, this should lead to improved clinical outcomes as measured by HbA1c. Other possible benefits of this new model of care include improved healthcare service delivery efficiency and patient and health professional satisfaction. This pilot study will inform recruitment yield, retention and acceptability from patients with T2DM and clinicians to guide the conduct of a large pragmatic RCT assessing the benefits of REMODEL-IDA for IDA in relevant patients across regional and remote Queensland, Australia. This has the potential to be integrated into the routine diabetes care of patients with T2DM in the community and regional Australia.

Supplemental Material {#section18-2042018819836647}
=====================

###### REMODEL-IDA_PICF_Patient_Information_and_Consent_FormV2_11022018 -- Supplemental material for Mobile-based insulin dose adjustment for type 2 diabetes in community and rural populations: study protocol for a pilot randomized controlled trial

###### 

Click here for additional data file.

Supplemental material, REMODEL-IDA_PICF_Patient_Information_and_Consent_FormV2_11022018 for Mobile-based insulin dose adjustment for type 2 diabetes in community and rural populations: study protocol for a pilot randomized controlled trial by Anish Menon, Leonard Gray, Farhad Fatehi, Dominique Bird, Darsy Darssan, Mohan Karunanithi and Anthony Russell in Therapeutic Advances in Endocrinology and Metabolism
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###### spirit_check_list\_ -- Supplemental material for Mobile-based insulin dose adjustment for type 2 diabetes in community and rural populations: study protocol for a pilot randomized controlled trial
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Click here for additional data file.

Supplemental material, spirit_check_list\_ for Mobile-based insulin dose adjustment for type 2 diabetes in community and rural populations: study protocol for a pilot randomized controlled trial by Anish Menon, Leonard Gray, Farhad Fatehi, Dominique Bird, Darsy Darssan, Mohan Karunanithi and Anthony Russell in Therapeutic Advances in Endocrinology and Metabolism
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###### Trial_Registration_Data_Set_1 -- Supplemental material for Mobile-based insulin dose adjustment for type 2 diabetes in community and rural populations: study protocol for a pilot randomized controlled trial
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Click here for additional data file.

Supplemental material, Trial_Registration_Data_Set_1 for Mobile-based insulin dose adjustment for type 2 diabetes in community and rural populations: study protocol for a pilot randomized controlled trial by Anish Menon, Leonard Gray, Farhad Fatehi, Dominique Bird, Darsy Darssan, Mohan Karunanithi and Anthony Russell in Therapeutic Advances in Endocrinology and Metabolism
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